TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

By sjmartinez • April 30, 2024

Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336. doi: 10.1177/17588359241248336. PMID: 38686016; PMCID: PMC11057345.

Tags: adjuvant therapy, antibody–drug conjugates, Hematology/Oncology, immunotherapy, Programmed cell death ligand-1, Publications, triple-negative breast cancer, trophoblast cell-surface antigen 2

STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer

Saeed A, Tabernero J, Parikh A, den Eynde MV, Karthaus M, Gerlinger M, Wang Z, Wang G, Smith R, Hecht JR. STELLAR-303: randomized phase III[...]

A Rare Case of Life-Threatening Hemorrhage

Soni M, Penn J. A Rare Case of Life-Threatening Hemorrhage. Cureus. 2024 Jun 21;16(6):e62878. doi: 10.7759/cureus.62878. PMID: 39040757; PMCID: PMC11261237.

Synchronous metastatic prostate cancer and male breast cancer while on testosterone replacement therapy: Case report

Cheng JJ, Shen J, Suresh Y, Akopyan NA, Kapoor NS. Synchronous metastatic prostate cancer and male breast cancer while on testosterone replacement therapy: Case report.[...]